Dr. Mookerjee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 Acorn Park Drive
Cambridge, MA 02140Phone+1 856-261-0153
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1991 - 1994
ArMed Forces Medical College PuneClass of 1987
Certifications & Licensure
PA State Medical License 2001 - 2024
MD State Medical License 1994 - 2003- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
Clinical Trials
- Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation Start of enrollment: 2000 Oct 01
- Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Start of enrollment: 2000 Jan 01
- AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. Start of enrollment: 2007 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 233 citationsCombined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.Antoni Ribas, Donald P. Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H. Miller
Nature Medicine. 2019-06-06 - 264 citationsRegulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.Rajani Ravi, Gauri. C. Bedi, Laura W. Engstrom, Qinwen Zeng, Bijoyesh Mookerjee
Nature Cell Biology. 2001-04-01 - 178 citationsComparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic ...Jean-Jacques Grob, Mayur M. Amonkar, Boguslawa Karaszewska, Jacob Schachter, Reinhard Dummer
The Lancet. Oncology. 2015-10-01
Press Mentions
Two Combination Therapies Shrink Melanoma Brain Metastases in More Than Half of PatientsJune 4th, 2017
Professional Memberships
- Member
- European Society of Medical OncologyMember
Other Languages
- Bengali
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
